Leerink says Regeneron's pre-announced Q4 Eylea sales of $24M-$25M dramatically exceed the consensus expectation of around $3M. The firm believes the company's 2012 Eylea sales guidance of $140M-$160M could prove conservative and reiterates an Outperform rating on the stock. Leerink raised its target range for shares to $76-$80. :theflyonthewall.com
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
